Telik Announces Publication Of A Report Of Complete Response Of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment With Telintra®

Background on Telintra

Telintra is an investigational agent in development for the treatment of a variety of neoplastic and non-neoplastic hematologic disorders, including myelodysplastic syndrome (MDS), and has demonstrated significant improvement in the induction of growth and differentiation of hematologic precursor stem cells as well as an increase in apoptosis of malignant cells.  Telintra is an inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1), a negative regulator of JNK.  Treatment of human cells with Telintra leads to the activation of JNK, which promotes the growth and differentiation of hematopoietic stem cell precursors.  Telintra treatment has shown significant improvement in neutrophil levels in several clinical trials in MDS.  More information about Telintra may be found at www.telik.com.  

About Telik, Inc.

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

This press release contains "forward-looking" statements regarding the future development of Telintra, the safety and effectiveness of Telintra in treating ICN and MDS, whether Telintra treatment results in hematologic improvement in patients with ICN and MDS, and the capability of Telintra to induce apoptosis in malignant cells and treat hematologic disorders in general.  These forward-looking statements are based upon Telik's current expectations and there are important factors that could cause actual results to differ materially from those indicated by these forward-looking statements.  Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ending June 30, 2011.  Telik does not undertake any obligation to update forward looking statements contained in this press release.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

« First ‹ Previous 1 2 3 Next › Last »